Plasma-lyte
Plasma-Lyte is a
intravenous infusion, with varying electrolyte formulation depending on market. Generally the solution has a composition that mimics human physiological plasma electrolyte concentrations, osmolality and pH.[1]
It is available as a
Plasma-lyte 148 (pH7.4)
Plasma-Lyte 148 is a market-specific solution available in the United Kingdom and Australia, among others and has the following composition:[citation needed]
Sodium 140 mmol/L
Potassium 5 mmol/L
Magnesium 1.5 mmol/L
Chloride 98 mmol/L
Acetate 27 mmol/L
Gluconate 23 mmol/L
This solution is manufactured and marketed by Baxter International Inc.[4]
References
- PMID 21841561.
- ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
- ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
- ^ 2: Baxter. Plasma-Lyte 148 product information. 2013. available at URL: http://www.baxterhealthcare.com.au/downloads/healthcare_professionals/cmi_pi/plasmalyte148_pi.pdf Archived 23 June 2017 at the Wayback Machine